Local allergic rhinitis: Concept, pathophysiology, and management - 31/05/12
, Paloma Campo, MD, PhD a, Alkis Togias, MD, PhD b, Wytske J. Fokkens, MD, PhD c, Stephen R. Durham, MD, PhD d, Desmond G. Powe, PhD e, Joaquim Mullol, MD, PhD f, Miguel Blanca, MD, PhD aAbstract |
Local allergic rhinitis (LAR) is a localized nasal allergic response in the absence of systemic atopy characterized by local production of specific IgE (sIgE) antibodies, a TH2 pattern of mucosal cell infiltration during natural exposure to aeroallergens, and a positive nasal allergen provocation test response with release of inflammatory mediators (tryptase and eosinophil cationic protein). Although the prevalence remains to be established, a number of patients previously given a diagnosis of nonallergic rhinitis or idiopathic rhinitis are now being classified as having LAR. Culprit allergens responsible include house dust mite, grass and olive pollens, and many others. For the diagnosis of LAR, neither skin prick testing nor determination of the presence of serum sIgE antibodies is useful, and a nasal allergen provocation test is needed to identify the culprit allergen or allergens. In a certain proportion of cases, local sIgE can be detected, and conjunctivitis, asthma, or both can be associated. Whether patients with LAR will have systemic atopy in the future is a matter of debate. Further studies are needed for examine the prevalence of this phenomenon in different areas, to improve the diagnostic methods to better identify these patients, and to develop therapeutic approaches, including the use of immunotherapy.
Le texte complet de cet article est disponible en PDF.Key words : Allergic rhinitis, eosinophil cationic protein, entopy, local allergic rhinitis, local specific IgE, nasal polyps, nonallergic rhinitis, nasal allergen provocation test, tryptase
Abbreviations used : AR, ECP, FLC, HDM, IR, LAR, NAPT, NAPT-S, NAR, NARES, SCIT, sIgE, SPT
Plan
| Disclosure of potential conflict of interest: W. J. Fokkens has received research support from GlaxoSmithKline and Medtronic and has served as an advisor to GlaxoSmithKline, MSD, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 129 - N° 6
P. 1460-1467 - juin 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
